Hepatitis C News

Patients who underwent liver transplantation evaluation had a high prevalence of coronary artery disease, especially those with nonalcoholic steatohepatitis-related cirrhosis, hepatitis C-related cirrhosis and alcoholic cirrhosis, according to a recently published study.

The safety and efficacy of Viekirax was comparable between patients with hepatitis C genotype 1b and chronic kidney disease and those without chronic kidney disease, according to a recently published study.

In patients with hepatitis C virus infection who were receiving opioid substitutes, interferon-free drug regimens yielded better outcomes compared with regimens containing interferon, according to researchers.

Data from a clinical trial showed that Harvoni for 12 or 24 weeks with or without ribavirin was safe and effective in treatment-experienced patients with hepatitis genotype 1 with cirrhosis.

The HepCom score — which combines Charlson Comorbidity Index, age, international normalized ratio, albumin and bilirubin — accurately detected patients with hepatitis C at high risk for 1- and 2-year mortality after the start of direct-acting antiviral therapy, according to recently published data.

For Eric Lawitz, MD, research is its own reward.

Douglas T. Dieterich, MD, director of the Institute for Liver Medicine at Mount Sinai Health Systems, and professor of medicine at the Icahn School of Medicine at Mount Sinai in New York, brings a unique perspective with him to work every day.

When Vincent Lo Re III, MD, MSCE, first entered the clinical epidemiology field, he did not know the rewarding career path on which it would lead him several years later.

Although Adrian M. Di Bisceglie, MD, FACP, is proud of the advancements made in hepatitis C treatments, he has come across a new challenge — ensuring patients do not become too complacent with their follow-up treatments.

HCV testing provides valuable information that aids in disease prevention and in the initiation of care.